|
|
|
ARCT Dividend History & Description — Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings is a clinical -stage messenger RNA medicines and vaccine company focused on the development of infectious disease vaccines and other opportunities within liver and respiratory rare diseases. Co.'s initial COVID-19 vaccine candidate, ARCT-021, was designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC. The LUNAR-CF program addresses cystic fibrosis lung disease. When considering the Arcturus Therapeutics Holdings Inc stock dividend history, we have taken known splits into account, such that the ARCT dividend history is presented on a split-adjusted ("apples to apples") basis. Arcturus Therapeutics Holdings Inc dividend history is presented both in graphical/chart form, and as a ARCT dividend history data table along the right-hand column.
Name: |
Arcturus Therapeutics Holdings Inc |
Website: |
www.arcturusrx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ARCT: |
30 (see which ones) |
Total Market Value Held by ETFs: |
$173,000,878.84 |
Total Market Capitalization: |
$936,000,000 |
% of Market Cap. Held by ETFs: |
18.48% |
|
ARCT Stock Dividend HistoryThe ARCT dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable ARCT historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the ARCT dividend history record. Also see the ARCT stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Strong Buy (3.56 out of 4)
64th percentile
|
|
|